Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study

Histopathology

Volumn 71, Issue 1, 2017, Pages 12-26

  Hynes, Seán O ^a   Coleman, Helen G ^b   Kelly, Paul J ^a,c   Irwin, Steven ^c   O'Neill, Roisin F ^b   Gray, Ronan T ^b   McGready, Claire ^a   Dunne, Philip D ^a   McQuaid, Stephen ^a,b,c   James, Jacqueline A ^a,b,c   Salto Tellez, Manuel ^a,c   Loughrey, Maurice B ^a,c  

^a Centre for Cancer Research and Cell Biology   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

colorectal cancer; inflammation; prognosis; stroma; survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PERITUMORAL LYMPHOID INFLAMMATION; PRIORITY JOURNAL; STAINING; TUMOR MICROENVIRONMENT; ADULT; COLON TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 85017356450     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.13181     Document Type: Article

References (40)

1. Arnold M, Sierra MS, Laversanne M et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2016; 66; 683–691.
2. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J. Clin. 2015; 65; 87–108.
3. Sinicrope FA, Shi Q, Smyrk TC et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 2015; 148; 88–99.
4. Phipps AI, Limburg PJ, Baron JA et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148; 77–87.
5. Guinney J, Dienstmann R, Wang X et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015; 21; 1350–1356.
6. Seretis F, Seretis C, Youssef H et al. Colorectal cancer: seed and soil hypothesis revisited. Anticancer Res. 2014; 34; 2087–2094.
7. Calon A, Lonardo E, Berenguer-Llergo A et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 2015; 47; 320–329.
8. Dunne PD, McArt DG, Bradley CA et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin. Cancer Res. 2016; 22; 4095–4104.
9. Isella C, Terrasi A, Bellomo SE et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 2015; 47; 312–319.
10. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987; 1; 1303–1306.
11. West NP, Dattani M, McShane P et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br. J. Cancer 2010; 102; 1519–1523.
12. Vayrynen JP, Sajanti SA, Klintrup K et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int. J. Cancer 2014; 134; 2126–2135.
13. Vayrynen JP, Tuomisto A, Klintrup K et al. Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br. J. Cancer 2013; 109; 1839–1847.
14. Ueno H, Shinto E, Shimazaki H et al. Histologic categorization of desmoplastic reaction: its relevance to the colorectal cancer microenvironment and prognosis. Ann. Surg. Oncol. 2015; 22; 1504–1512.
15. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat. Rev. 2012; 38; 451–466.
16. Roxburgh CS, Salmond JM, Horgan PG et al. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur. J. Cancer 2009; 45; 2138–2145.
17. Richards CH, Flegg KM, Roxburgh CS et al. The relationships between cellular components of the peritumoral inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br. J. Cancer 2012; 106; 2010–2015.
18. Pages F, Kirilovsky A, Mlecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009; 27; 5944–5951.
19. Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 2009; 15; 6412–6420.
20. Mesker WE, Junggeburt JM, Szuhai K et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol. 2007; 29; 387–398.
21. Klintrup K, Makinen JM, Kauppila S et al. Inflammation and prognosis in colorectal cancer. Eur. J. Cancer 2005; 41; 2645–2654.
22. Huijbers A, Tollenaar RA, v Pelt GW et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann. Oncol. 2013; 24; 179–185.
23. Graham DM, Appelman HD. Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod. Pathol. 1990; 3; 332–335.
24. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 2014; 232; 199–209.
25. Ropponen KM, Eskelinen MJ, Lipponen PK et al. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol. 1997; 182; 318–324.
26. Park JH, Richards CH, McMillan DC et al. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann. Oncol. 2014; 25; 644–651.
27. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005; 353; 2654–2666.
28. Fridman WH, Galon J, Pages F et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011; 71; 5601–5605.
29. Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370; 2020–2029.
30. Kennedy RD, Bylesjo M, Kerr P et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J. Clin. Oncol. 2011; 29; 4620–4626.
31. Niedzwiecki D, Frankel WL, Venook AP et al. Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (Alliance). J. Clin. Oncol. 2016; 34; 3047–3053.
32. Hamilton SR, Bosman FT, Boffetta P et al. Carcinoma of the colon and rectum. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. World Health Organization classification of tumours of the digestive system. Lyon: IARC Press, 2010; 105–115.
33. Mei Z, Liu Y, Liu C et al. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br. J. Cancer 2014; 110; 1595–1605.
34. Cyster JG. Lymphoid organ development and cell migration. Immunol. Rev. 2003; 195; 5–14.
35. Rozek LS, Schmit SL, Greenson JK et al. Tumor-infiltrating lymphocytes, Crohn's-like lymphoid reaction, and survival from colorectal cancer. J. Natl Cancer Inst. 2016; 108; pii: djw027.
36. Loughrey MB, Quirke P, Shepherd NA. Standards and datasets for reporting cancers: dataset for colorectal cancer histopathology reports. London: Royal College of Pathologists, 2014.
37. Tang LK, Berlin J, Branton P et al. College of American Pathologists: protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. 2016. Accessed 1 November 2016; http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-colon-16protocol-3400.pdf.
38. Moehler M, Delic M, Goepfert K et al. Immunotherapy in gastrointestinal cancer: recent results, current studies and future perspectives. Eur. J. Cancer 2016; 59; 160–170.
39. Dunne PD, McArt DG, O'Reilly PG et al. Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis who may be harmed by adjuvant chemotherapy. Cancer Immunol. Res. 2016; 4; 582–591.
40. Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016; 44; 698–711.